| A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study PC Austin, P Grootendorst, GM Anderson Statistics in medicine 26 (4), 734-753, 2007 | 1415 | 2007 |
| The cost of drug development: a systematic review S Morgan, P Grootendorst, J Lexchin, C Cunningham, D Greyson Health policy 100 (1), 4-17, 2011 | 788 | 2011 |
| Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. AR Levy, BJ O'Brien, C Sellors, P Grootendorst, D Willison The Canadian journal of clinical pharmacology= Journal canadien de …, 2003 | 597 | 2003 |
| Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study PC Austin, P Grootendorst, SLT Normand, GM Anderson Statistics in medicine 26 (4), 754-768, 2007 | 275 | 2007 |
| Health Utilities Index Mark 3: evidence of construct validity for stroke and arthritis in a population health survey P Grootendorst, D Feeny, W Furlong Medical care 38 (3), 290-299, 2000 | 262 | 2000 |
| Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence J Lexchin, P Grootendorst International Journal of Health Services 34 (1), 101-122, 2004 | 242 | 2004 |
| An empirical analysis of milk addiction MC Auld, P Grootendorst Journal of health economics 23 (6), 1117-1133, 2004 | 195 | 2004 |
| Cost analysis of dialysis treatments for end-stage renal disease (ESRD). R Goeree, J Manalich, P Grootendorst, ML Beecroft, DN Churchill Clinical and investigative medicine. Medecine clinique et experimentale 18 …, 1995 | 162 | 1995 |
| A comparison of alternative models of prescription drug utilization PV Grootendorst Health Economics 4 (3), 183-198, 1995 | 157 | 1995 |
| Estimating the clinical cost of drug development for orphan versus non-orphan drugs K Jayasundara, A Hollis, M Krahn, M Mamdani, JS Hoch, P Grootendorst Orphanet journal of rare diseases 14 (1), 12, 2019 | 156 | 2019 |
| Dental insurance, income and the use of dental care in Canada T Bhatti, Z Rana, P Grootendorst J Can Dent Assoc 73 (1), 57, 2007 | 156 | 2007 |
| Does it matter whom and how you ask? Inter-and intra-rater agreement in the Ontario Health Survey PV Grootendorst, DH Feeny, W Furlong Journal of clinical epidemiology 50 (2), 127-135, 1997 | 140 | 1997 |
| Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada P Contoyannis, J Hurley, P Grootendorst, SH Jeon, R Tamblyn Health economics 14 (9), 909-923, 2005 | 122 | 2005 |
| Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology Y Li, MR Abbaspour, PV Grootendorst, AM Rauth, XY Wu European Journal of Pharmaceutics and Biopharmaceutics 94, 170-179, 2015 | 115 | 2015 |
| Economic instruments for obesity prevention: results of a scoping review and modified Delphi survey GEJ Faulkner, P Grootendorst, VH Nguyen, T Andreyeva, ... International Journal of Behavioral Nutrition and Physical Activity 8 (1), 109, 2011 | 105 | 2011 |
| Use of instrumental variables in the analysis of generalized linear models in the presence of unmeasured confounding with applications to epidemiological research KM Johnston, P Gustafson, AR Levy, P Grootendorst Statistics in medicine 27 (9), 1539-1556, 2008 | 100 | 2008 |
| Becoming the best mom that I can: women's experiences of managing depression during pregnancy–a qualitative study HA Bennett, HS Boon, SE Romans, P Grootendorst BMC women's health 7 (1), 13, 2007 | 94 | 2007 |
| Beneficiary cost sharing under Canadian provincial prescription drug benefit programs: history and assessment. P Grootendorst The Canadian journal of clinical pharmacology= Journal canadien de …, 2002 | 91 | 2002 |
| Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs PV Grootendorst, LR Dolovich, BJ O'Brien, AM Holbrook, AR Levy Cmaj 165 (8), 1011-1019, 2001 | 87 | 2001 |
| Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia JK Marshall, PV Grootendorst, BJ O'Brien, LR Dolovich, AM Holbrook, ... Cmaj 166 (13), 1655-1662, 2002 | 84 | 2002 |
